EyePoint Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
EyePoint Pharmaceuticals has a total shareholder equity of $228.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $324.2M and $95.9M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$280.25m |
| Equity | US$228.31m |
| Total liabilities | US$95.94m |
| Total assets | US$324.25m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: PV3B's short term assets ($294.9M) exceed its short term liabilities ($62.1M).
Long Term Liabilities: PV3B's short term assets ($294.9M) exceed its long term liabilities ($33.8M).
Debt to Equity History and Analysis
Debt Level: PV3B is debt free.
Reducing Debt: PV3B has no debt compared to 5 years ago when its debt to equity ratio was 163.9%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PV3B has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PV3B has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 1.3% each year.